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Antiepileptic drug resistant rats differ from drug responsive rats
in GABA A receptor subunit expression in a model of temporal
lobe epilepsy
Abstract
Epidemiological data indicate that 20-40% of the patients with epilepsy are refractory to treatment with
antiepileptic drugs (AEDs). The mechanisms underlying pharmacoresistance in epilepsy are unclear, but
several plausible hypotheses have emerged, including loss of AED target sensitivity in the epileptic
brain, decreased AED concentrations at brain targets because of localized overexpression of drug efflux
transporters in epileptogenic brain tissue, and network alterations in response to brain damage associated
with epilepsy. Rat models of epilepsy in which part of the animals are resistant to treatment with AEDs
offer a means to investigate the mechanisms underlying AED resistance. In the present study,
AED-responsive and AED-resistant rats were selected from a model in which spontaneous recurrent
seizures develop after a status epilepticus induced by electrical stimulation of the basolateral amygdala.
For selection into responders and nonresponders, epileptic rats were treated over two weeks by
phenobarbital. Subsequent histological examination showed neurodegeneration of the CA1, CA3 and
dentate hilus in only one of eight responders but five of six nonresponders (P=0.0256). Based on
previous studies in AED-resistant rats of this model, we hypothesized that changes in the structure and
function of inhibitory GABA(A) receptors may contribute to drug resistance. We therefore analyzed the
distribution and expression of several GABA(A) receptor subunits (alpha1, alpha2, alpha 3, alpha 4,
alpha 5, beta2/3, and gamma 2) immunohistochemically with specific antibodies in the hippocampal
formation of responders, nonresponders and nonepileptic controls. In nonresponders, decreased subunit
staining was observed in CA1, CA2, CA3, and dentate gyrus, whereas much less widespread alterations
were determined in responders. Furthermore, upregulation of the alpha 4-subunit was observed in the
CA1 of nonresponders. Our data suggest that alterations in GABA(A) receptor subtypes may be
involved in resistance to AEDs.
www.elsevier.com/locate/ynbdi
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Available online 4 February 2008Epidemiological data indicate that 20–40% of the patients with epilepsy
are refractory to treatment with antiepileptic drugs (AEDs). The mecha-
nisms underlying pharmacoresistance in epilepsy are unclear, but several
plausible hypotheses have emerged, including loss of AED target sensi-
tivity in the epileptic brain, decreasedAEDconcentrations at brain targets
because of localized overexpression of drug efflux transporters in epilep-
togenic brain tissue, and network alterations in response to brain damage
associated with epilepsy. Rat models of epilepsy in which part of the
animals are resistant to treatment with AEDs offer a means to investigate
the mechanisms underlying AED resistance. In the present study, AED-
responsive and AED-resistant rats were selected from a model in which
spontaneous recurrent seizures develop after a status epilepticus induced
by electrical stimulation of the basolateral amygdala. For selection into
responders and nonresponders, epileptic rats were treated over twoweeks
by phenobarbital. Subsequent histological examination showed neurode-
generation of the CA1, CA3 and dentate hilus in only one of eight res-
ponders but five of six nonresponders (P=0.0256). Based on previous
studies in AED-resistant rats of this model, we hypothesized that changes
in the structure and function of inhibitory GABAA receptors may contri-
bute to drug resistance. We therefore analyzed the distribution and ex-
pression of severalGABAA receptor subunits (α1,α2,α3,α4,α5,β2/3,
and γ2) immunohistochemically with specific antibodies in the hippo-
campal formation of responders, nonresponders and nonepileptic controls.
In nonresponders, decreased subunit staining was observed in CA1, CA2,
CA3, and dentate gyrus, whereas much less widespread alterations were
determined in responders. Furthermore, upregulation of the α4-subunit
was observed in the CA1 of nonresponders. Our data suggest that altera-
tions in GABAA receptor subtypes may be involved in resistance to AEDs.
© 2008 Published by Elsevier Inc.
Keywords: GABA; Phenobarbital; Pharmacoresistance; Hippocampus;
Dentate gyrus⁎ Corresponding author. Department of Pharmacology, Toxicology, and
Pharmacy, University of Veterinary Medicine Hannover, Bünteweg 17, D-
30559, Hannover, Germany. Fax: +49 511 953 8581.
E-mail address: wolfgang.loescher@tiho-hannover.de (W. Löscher).
Available online on ScienceDirect (www.sciencedirect.com).
0969-9961/$ - see front matter © 2008 Published by Elsevier Inc.
doi:10.1016/j.nbd.2008.01.005Introduction
Epilepsy is one of themost common serious brain disorders, and is
associated with an increased risk of comorbidities and mortality
(Chang and Lowenstein, 2003). Despite the availability of various
newly developed antiepileptic drugs (AEDs), pharmacoresistance
remains a major challenge in epilepsy management (Schmidt and
Löscher, 2005). Unravelling the mechanisms underlying AED
resistance has been the focus of intense efforts to develop new
rationally designed therapies for as yet refractory epilepsies. Based on
experimental and clinical studies, two major neurobiological theories
have been put forward: (a) the multidrug transporter hypothesis,
which suggests that increased brain expression of drug efflux tran-
sporters such as P-glycoprotein (P-gp) decreases AED levels at their
brain targets, and (b) the target hypothesis, which suggests that AEDs
are not effective because of target alterations in epileptogenic brain
tissue (Löscher and Potschka, 2005; Remy and Beck, 2006). Most
AEDs exert their effects either by modulation of voltage-dependent
ion channels or by enhancing the inhibitory action of GABA
(Rogawski and Löscher, 2004). There is some evidence that resistance
to Na+ channel modulators such as carbamazepine may be due to
target alterations in epileptogenic tissue of patients with refractory
epilepsy (Remy and Beck, 2006). However, as yet no such clinical
evidence is available for otherAED targets such as GABAA receptors.
Animal models of epilepsy provide a means to investigate fun-
damental mechanisms underlying the development of epilepsy and
AED resistance in epilepsy (Löscher, 2006). Combinedmolecular and
functional studies in rat models of temporal lobe epilepsy (TLE)
indicate a transcriptionally mediated switch in the alpha subunit
composition of GABAA receptors in the hippocampal formation,
characterized by a decrease of α1 subunits and an increase of α4
subunits in epileptic animals compared to controls (Brooks-Kayal
et al., 1998; Coulter, 2000). This switch in the alpha subunit com-
position is associatedwith a reduced in vitro sensitivity toAEDs acting
on the benzodiazepine site of the GABAA receptor (Coulter, 2001).
However, none of these studies evaluatedwhether these changes in the
GABAA receptor subunit expression in the hippocampus of epileptic
Fig. 1. Schematic illustration of the experimental protocol used for the present study.
Table 1
Neurodegeneration in the hippocampal formation of rats with spontaneous
recurrent seizures
Rats Seizure
load
during
control
periods
Neuronal loss in the hippocampal formation
(scores)
CA1 CA3a CA3c/CA4 Dentate hilus
Responders
NIH 4 17 0 0 0 0
NIH 21 3 0 0 0 0
NIH 23 17 0 0 0 1
NIH 25 4 0 0 0 0
NIH 31 8 0–1 0 0 0
Nonresponders
NIH 6 10 3 3 2 3
NIH 8 7 3 3 2–3 3
NIH 13 15 0 0 0 2
NIH 17 5 2 0 0 2
NIH 18 406 2 0 0–2 3
Alterations were semiquantitatively assessed by a grading system as described in
the Materials andmethods section. Ratswere grouped according to their response
to phenobarbital into responders and nonresponders (see Fig. 2). By comparison
with nonepileptic controls (not included in the table), no unambiguous indication
of neurodegeneration (i.e., a score of at least 2)was seen in responders. In contrast,
all nonresponders exhibited different patterns of hippocampal cell damage as
indicated in the table. The most common damage in nonresponders was cell loss
in the dentate hilus. In most rats, no differences between hemispheres were
observed, so that data are not shown separately for the right and left hemisphere. If
there was a difference between hemispheres, scores for both hemispheres are
shown (e.g., “2–3”). In addition to histological alterations, the seizure load is
shown for each rat as total number of seizures recorded over four control weeks
(i.e., two weeks predrug and two weeks postdrug).
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AED treatment, so that the relationship, if any, of the altered subunit
composition for in vivo AED resistance is not known.
In a recent study in a rat model of TLE, we categorized epileptic rats
into AED responders and nonresponders by prolonged treatment with
phenobarbital (PB) and used GABAA receptor autoradiography to
analyze the regional distribution of diazepam-sensitive and -insensitive
binding sites on GABAA receptors (Volk et al., 2006). A marked
enhancement of diazepam-insensitive binding was observed in the
dentate granule cells of nonresponders compared to both responders and
controls, whereas this was not observed in the hilus or CA1, suggesting
a selective upregulation of diazepam-insensitive GABAA receptors in
the dentate gyrus granule cells of nonresponders (Volk et al., 2006).
These data thus suggested that the target hypothesis of drug resistant
epilepsy may include GABAA receptors.
For further evaluation of this hypothesis, we repeated the selection
of PB-responders and nonresponders and used GABAA receptor
subunit immunohistochemistry to determine whether responders and
nonresponders differ in their alpha subunit expression. Highly
selective antibodies for the α1, α2, α3, α4 and α5 subunits were
used for this purpose (Fritschy et al., 1992, 1999; Fritschy andMöhler,
1995). Furthermore, the β2/3 and γ2 subunits of the GABAA receptor
were included in the study. In addition to characterizing the alpha
subunit expression in PB-responders and nonresponders, we
compared the morphological changes in the hippocampal formation
in the two groups, because neuron loss affects the expression of
GABAA receptor subunits. In a recent study, hippocampal damage
was only determined in PB-nonresponders, whereas the hippocampus
of PB-responders did not differ from non-epileptic controls (Volk
et al., 2006). Because the group size in this recent study was relatively
small, we evaluated in the present study whether the difference
in brain damage between responders and nonresponders can be
reproduced in larger groups.
Materials and methods
Animals
As in our previous experiments in rats with spontaneous
recurrent seizures (SRS) developing after status epilepticus (SE)induced by prolonged electrical stimulation of the basolateral
amygdala (BLA) (Brandt et al., 2004; Volk and Löscher, 2005;
Volk et al., 2006), adult female Sprague–Dawley rats (Harlan-
Winkelmann, Borchen, Germany) were used for this study. All
animal experiments were carried out in accordance with the
European Communities Council Directive of 24. November 1986
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review board of our institution. All efforts were made to minimize
the number of animals used and their suffering.
Electrode implantation and SE induction
A bipolar electrode was stereotactically implanted into the right
anterior BLA under anesthesia as described in detail recently (Brandt
et al., 2003) and served for electrical stimulation and recording of
the electroencephalogram (EEG). About four weeks after electrode
implantation, 25 rats were electrically stimulated via the BLA elec-
trode for induction of a self-sustained SE as described previously
(Brandt et al., 2003, 2004; Volk and Löscher, 2005). The following
stimulus parameters were chosen: stimulus duration 25 min; stimulus
consisting of 100 m trains of 1 ms alternating positive and negative
squarewave pulses. The trainswere given at a frequency of 2/s and the
intra-train pulse frequencywas 50/s. Peak pulse intensity was 700 μA.
For this pulsed-train stimulation, an Accupulser A310C stimulator
connected with a Stimulus Isolator A365 (World Precision Instru-
ments, Berlin, Germany) was used. In all rats, the EEG was recordedFig. 2. Effect of phenobarbital (PB) on spontaneous recurrent seizures (SRS) in rats
(predrug control), followed by drug treatment for two weeks, and then a two-week p
show the average number of seizures per day recorded over the three two-week pe
blood samples taken during the treatment period. In “A”, average seizure data from t
“B” shows respective data from the five responders and “C” data from the five nonres
of the ordinate in “B” is different from the scales used in “A” and “C” in order to illus
of data by ANOVA indicated significant differences between treatment and control
(P=0.3896). Posthoc analysis indicated that in the responder group PB significa
indicated by asterisk). Plasma levels of PB (D) did not significantly differ between gr
and postdrug control periods than responders, which, however, was not statistically s
(range in nonresponders 0.14–9.17 seizures/day during predrug and 0.21–19.7 seizu
in responders, respectively). The apparently higher average control seizure frequenc
20 seizures per day, whereas the other nonresponders did not differ in control seizuvia the BLA electrode during SE and up to 20 h after termination
of SE by diazepam (see below). Only rats which developed a self-
sustained SE with generalized convulsive seizures were used for
further experiments. SEwas interrupted after 4 h by diazepam (10mg/
kg i.p.). If necessary, the application of this dose of diazepam was
repeated. Starting six weeks later, the rats were monitored by EEG-
video-recordings for 1 week for detection of spontaneous seizures as
described recently (Brandt et al., 2003, 2004). Fifteen rats with SRS
were used for selection of responders and nonresponders by
prolonged treatment with PB. Eight age-matched rats that were
implanted with BLA electrodes but not stimulated were used as sham
controls. Furthermore, 7 age-matched animals without BLA electro-
des served as naive controls.
Selection of responders and nonresponders
PB was chosen because it is an efficacious AED in rat models
of TLE with a sufficiently long half-life (17 h in female Sprague–
Dawley rats) to allow maintenance of “therapeutic” drug levels
during prolonged treatment (Löscher and Hönack, 1989; Leite and. SRS were recorded over a period of two weeks before onset of PB treatment
ostdrug control period. All data are shown as means±SEM. “A”, “B” and “C”
riods, while “D” illustrates the average plasma concentration of PB from the
he 10 rats later used for analysis of GABAA receptor subunits are given, while
ponders of this group (see text for definitions). It should be noted that the scale
trate the marked anticonvulsant effect of PB in the responder group. Analysis
periods for the responder group (P=0.0085) but not the nonresponder group
ntly suppressed SRS compared to the pre- and postdrug periods (Pb0.05;
oups. On average, nonresponders tended to havemore seizures during predrug
ignificant because of the large inter-individual variation in seizure frequencies
res/day during postdrug control vs. 0.071–0.35 and 0.071–0.86 seizures/day
y in nonresponders was mainly due to one rat (NIH 18) which exhibited up to
re frequencies from responders (see Table 1).
Fig. 3. Representative thionin-stained coronal sections of the hippocampal
formation of a non-epileptic control rat (A, B), an epileptic rat responding to
treatment with phenobarbital (C, D), and a rat not responding to treatment
with phenobarbital (E, F). While the responder (NIH 21) did not differ from
controls, the nonresponder (NIH 8) showed neuronal damage in the CA1,
CA3a and dentate hilus, whereas the CA2 was at least partially spared from
damage. Other sections from the same nonresponder showed also damage in
CA3c/CA4 (see Table 1). Calibration bar in “A” (for A, C and E)=500 μm;
calibration bar in B (for B, D and F)=100 μm. All panels are from the right
(ipsilateral) hemisphere.
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recently (Brandt et al., 2004), several preliminary experiments
were performed to develop a dosing protocol with maximum
tolerable doses, resulting in maintenance of plasma drug con-
centrations within or above the therapeutic range (10–40 μg/ml;
Baulac, 2002) over 24 h/day, 7 days/week. Based on these pre-
liminary experiments, a dosing protocol with an i.p. bolus dose of
25 mg/kg in the morning of the first treatment day, followed 10 h
later by an administration of 15 mg/kg i.p., and then twice daily
15 mg/kg i.p. for the 13 subsequent days, was used in rats with
SRS. For drug administration, the sodium salt of PB was dissolved
in 0.9% saline and administered at a volume of 3 ml/kg. Before
onset of drug treatment, baseline seizure frequency was determined
over two weeks (predrug control period, which started about eight
weeks after the SE), then PB was administered over two weeks,
followed by a postdrug control period of two weeks (Fig. 1). In
this way, each animal served as its own control, accounting for
differences between animals, e.g., variability in baseline seizure
frequency. During the predrug control period, 0.9% saline (3 ml/
kg) was injected instead of PB. During drug treatment, rats were
closely observed for adverse effects (ataxia, sedation, muscle
relaxation). Blood was sampled by retroorbital puncture (after local
anesthesia with tetracaine) 10 h after the first drug injection, 10 h
after drug injection on day 7, and 10 h after the last drug injection
for PB analysis in plasma by high-performance liquid chromato-
graphy (HPLC) with ultraviolet detection (Potschka et al., 2002).
In all rats, seizures were continuously (24 h/day, 7 days/week)
monitored by video/EEG-recording over the six weeks of the
experiment as described below.
Monitoring and analysis of spontaneous recurrent seizures
For continuous depth EEG-monitoring via the BLA electrode,
an 8-channel amplifier (CyberAmp 380, Axon Instruments, Inc.
Foster City, CA, USA), eight 1-channel bioamplifiers (ADInstru-
ments Ltd., Hastings, East Sussex, UK), and two analogue–digital
converters (PowerLab/800s, ADInstruments Ltd) were used. This
system allowed simultaneous recording of EEGs from up to 16
rats, so that all of the 15 rats used in this study could be recorded
continuously over the experimental periods. The data were re-
corded and analyzed with the Chart4 for windows software
(ADInstruments Ltd, Hastings, East Sussex, UK). The sampling
rate for the EEG-recording was 200 Hz. A high pass filter for
0.1 Hz and a low pass filter for 60 Hz were used.
Simultaneous to the EEG-recording, all rats used in this study
were video-monitored continuously during the experimental per-
iods, using four light-sensitive black–white cameras (CCD-Kamera-
Modul, Conrad Electronic, Hannover, Germany) which allowed
video-recording of up to four rats per camera. The cameras were
connected to a multiplexer (TVMP-400, Monacor, Bremen,
Germany) which converted the signals from the four cameras to a
video recorder (Time Lapse recorder, Sanyo TLS-9024P, Monacor,
Bremen, Germany). To allow video-recording of seizures during the
night, the animal room was weakly illuminated by red light during
the dark phase. Rats were housed in clear glass cages (one per cage)
to allow optimal video observation.
For detection of spontaneous seizures, the EEG recordings were
visually analyzed for characteristic ictal events. To evaluate the
severity of motor seizure activity during a paroxysmal alteration
in the EEG, the corresponding video-recording was viewed. In
addition to seizures observed by video and EEG recordings, seizuresobserved during handling or other manipulations of the animals
were noted. As described previously (Brandt et al., 2003, 2004),
most spontaneous seizures were generalized convulsive seizures,
resembling stage 4 or 5 seizures of the Racine scale (Racine, 1972).
Based on individual responses of rats to treatment, they were either
considered responders or nonresponders. Responders were defined
by complete inhibition of seizures during treatment or a reduction in
the frequency of seizures of N75% compared to seizure frequency in
the control periods.
Tissue preparation and histology
After termination of the drug experiment, the rats were deeply
anesthetized with chloral hydrate (500 mg/kg) and perfused through
the ascending aorta with 100 ml phosphate buffered saline (PBS) at
37 °C, followed by up to 500 ml fixative at 4 °C. The fixative
contained 4% paraformaldehyde and 15% of a saturated solution
of picric acid in phosphate buffer (0.15 M, pH 7.4; Somogyi and
Tagaki, 1982). Brains were removed immediately after the per-
fusion, postfixed for 90 min in ice-cold fixative, and stored over-
night at 4 °C in 10% sucrose-solution to ensure cryoprotection. The
following day, brains were transferred to 30% sucrose-solution until
the brains sank to the bottom (24–48 h). Six series of 40-μm thick
transversal sections were cut on a freezing microtome and collected
in PBS (pH 7.4).
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cytoarchitectonic boundaries of the hippocampal formation, visually
analyze neurodegeneration in the hippocampal formation, measure
the area of the hilus, and determine the number and density (neurons
per unit area) of hilar neurons.
Three sections in the ipsilateral and contralateral hippocampal
formation were analyzed for damage in each rat. These sections were
located at 240 μm intervals between 2.4 and 5.5 mm posterior from
bregma according to the atlas of Paxinos and Watson (1998). In the
first step, thionin-stained sections of the following subregions of the
hippocampal formation were visually inspected for damage: CA1,
CA2, CA3a, CA3c/CA4, dentate gyrus, and hilus. Severity of
neuronal damage in a section was semiquantitatively assessed by a
grading system similar to that previously described by Halonen et al.
(2001), Cilio et al. (2001) and Brandt et al. (2003) as follows: score
0, no obvious damage; score 1, apparent alteration of morphology,
but no unambiguous lesion; score 2, clear-cut lesions involving 20–
50% of neurons; and score 3, clear-cut lesions involving N50% of
neurons. In this respect, it is important to note that neuronal lossmust
exceed 15% to 20% before it is reliably detected by visual inspection
(Fujikawa et al., 2000). Visual assessment was conducted blindly
with respect to the treatment status of the animal. The maximum
score observed in sections from each hippocampal subregion per rat
was used for calculating group means.
Prompted by the data from visual inspection of sections, in a
second step the number and density (neurons per unit area) of
polymorph neurons (i.e., mossy cells and interneurons) wereFig. 4. Quantification of neuronal damage in the hippocampal formation. Data are f
used for GABAA receptor subunit analyses plus age-matched naive and sham contr
polymorphic neurons in the hilus of the dentate gyrus. (B) Number of neurons in
sections of the hilus. In “C”, the severity of damage in the CA1 sector was rated
involving N50% of neurons). The same grading system was used in “D” to assess th
all scores were zero. Statistical analysis of data by ANOVA (separately for each he
significantly (Pb0.05). Posthoc analyses indicated that nonresponders differed
significantly differ from controls.determined in the dentate hilus of the hippocampal formation. The
hilus was defined by the inner edge of the granule cell layer and
lines connecting the tips of the two granule cell blades to the
beginning of the CA3c/CA4 pyramidal cell layer of Ammon's
horn. All measurements were made ipsilateral and contralateral to
the stimulation site. All evaluations were conducted blind with
respect to the treatment status of the rat by the same experienced
researcher. Hilar neurons were counted in three sections at about
−2.8, −3.8, and −4.8 mm posterior from bregma within the
boundaries of the hilus described above. Neuronal densities
(neurons/mm2) were calculated by dividing the neuronal number
by the area of the hilus. For each hemisphere, the values of the
neuronal number and density from each of the three sections were
averaged to a single value for each animal. The area of the hilus
was determined in each section by an image analysis system
(KS400; Zeiss, Germany).
Immunohistochemistry
For immunohistochemical analyses of GABAA receptor sub-
units, 5 rats were randomly chosen from the responder, nonrespon-
der, sham and naive control groups, respectively (Fig. 1). The
regional distribution of GABAA receptor subunits α1–5, β2/3, δ and
γ2 was visualized in sections processed for immunoperoxidase
staining (Hsu et al., 1981) with subunit-specific antibodies (Fritschy
and Möhler, 1995; Sperk et al., 1997). Antibodies to the α1, α4,
δ-subunits were raised in rabbits, antibodies to α2, α3, α5 and γ2 wererom the five phenobarbital-responders and five phenobarbital-nonresponders
ols. Data are shown as means±SEM. (A) Density (neurons per unit area) of
the hilus, shown as the average neuron number counted in three adjacent
by a grading systems with scores ranging from 0 (no damage) to 3 (lesions
e severity of damage in CA3c (also termed CA4). Lack of bars indicates that
misphere) indicated that the four groups of rats shown in each panel differed
significantly from all other groups (Pb0.05), while responders did not
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(monoclonal antibody bd-17). Antibodies were either produced by the
Zurich group (α1, α2, α3, α5, γ2) as described previously (Fritschy
and Möhler, 1995) or obtained from W. Sieghart (α4, δ) and from
Chemicon, Hofheim (β2/3). All secondary antibodies were raised in
goat (Jackson Immunoresearch, West Grove, PA). Free-floating
sections were washed 3× 10 min in Tris buffer (Tris saline, pH 7.4)
and incubated at 4 °C overnight in primary antibody solution diluted
in Tris buffer containing 2% normal goat serum, 2% rat serum and
0.2% Triton X-100. The following antibody dilutions were used: α1,
β2/3: 1:20,000; α2: 1:750; α3: 1:4000; α4, δ, γ2: 1:2000; α5: 1:3000.
Sections were then washed 3× 10 min in Tris buffer and incubated in
biotinylated secondary antibody solution (Jackson Immunoresearch)
diluted 1:300 in Tris saline containing 2% normal goat serum for
30 min at room temperature. After additional washing, sections were
transferred to the avidin–peroxidase solution (Vectastain Elite Kit,
Vector Laboratories) for 30 min, washed, and processed using
diaminobenzidine hydrochloride (DAB, Sigma) as chromogen. Slides
were air-dried, dehydratedwith an ascending series of ethanol, cleared
in xylene and coverslipped with Eukitt. In control experiments, noFig. 5. Comparison of immunohistochemical labeling for the α1-subunit of the GA
control (A–C), a sham control (D–F), a phenobarbital-responsive (NIH 25; G–I) an
high magnification photomicrographs of the dentate hilus and C, F, I and L high ma
in A=500 μm (for A, D, G, J), in B=200 μm (for B, E, H, K), in C=200 μm (fospecific staining was detected upon pre-absorption of the primary
antibodies with their respective peptide antigen.
To reduce variation in staining intensity between different sec-
tions, all sections stained for one GABAA receptor subunit were
processed together. Per rat, 6 sections were used per antibody, so that
120 sections from the 20 rats were processed together per GABAA
receptor subunit. Unfortunately, the δ-subunit could not be finally
evaluated because staining was too weak to allow reliable analysis of
differences in subunit expression between treatment groups. No
sections were left to repeat the immunohistochemical analyses of the
δ subunit.
Image analysis
Analysis of changes in the regional distribution of GABAA
receptor subunits in the hippocampal formation was performed by
semi-quantitative image analysis of relative optical density (OD) in
DAB-stained sections by a computer-assisted system. The hard-
ware consisted of an Axioskop microscope with a Plan-Neofluar
lens (Zeiss, Germany), a single chip charge coupled device (CCD)BAA receptor in coronal sections of the hippocampal formation of a naive
d a phenobarbital-resistant (NIH 13; J–L) epileptic rat. B, E, H and K show
gnification photomicrographs of the CA1 sector of the same rats. Scale bars:
r C, F, I, L). All panels are from the right (ipsilateral) hemisphere.
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many), and a computer equipped with an image capture interface
card (V7-Mirage, Spea, USA). For analysis of brain sections, a
400× magnification was used. The captured images were 1300×
1030 pixels in dimension and were processed by the means of the
image analysis software KS400 (Windows Release 3.0, Carl Zeiss
Vision, Germany) essentially as described by us recently (Volk
et al., 2004; Volk and Löscher, 2005) for analysis of P-glycoprotein
in brain sections. Field densitometry was carried out in different
hippocampal subregions in both hemispheres: dentate gyrus
(granule cell and molecular layers), dentate hilus, CA1, CA2
(only for α5) and CA3 of the cornu ammonis. For CA1, CA2 and
CA3, stratum pyramidale, stratum oriens and stratum radiatum
were included in the analyses. In each region, fields of 38,321 μm2
were chosen for analysis of subunit expression, using 3–10 fields
per section level to cover the whole extension of each area (3 fields
for the hilus, 5 fields for CA1 and CA3, and 10 fields for the upper
and lower blades of the dentate gyrus, respectively). OD was
measured directly from the digitized images. Calibration of OD
was performed by a standard OD curve (Calibration of Step Tablet
No. 507ST101, Eastman Kodak Company, New York, USA). The
illumination was kept constant and was checked regularly during
the measurement with the standard curve. In addition to using field
densitometry for analysis of receptor subunit expression, we
measured the expression of the α4 subunit in CA1 pyramidal cells
by using the interactive measurement tools of the AxioVision
image processing and analysis system (Zeiss).Fig. 6. Comparison of immunohistochemical labeling for the α2-subunit of the GA
control (A–C), a phenobarbital-responsive (NIH 21; D–F) and a phenobarbital-
tion photomicrographs of the dentate hilus and C, F and I high magnification photom
A, D, G), in B=200 μm (for B, E, H), in C=200 μm (for C, F, I). All panels areStatistics
Seizure frequencies were not normally distributed, so that
nonparametric statistics were used for within-group comparisons
(Friedman test, followed by theWilcoxon signed rank test for paired
replicates) and inter-group comparisons (Mann–Whitney U-test).
For group comparisons of PB levels, ANOVA followed by the
Bonferroni multiple comparison test was used. Differences between
groups in neuron numbers and densities in the hilus and in ex-
pression of GABAA receptor subunits were analyzed by ANOVA
followed by the Bonferroni multiple comparison test. For group
comparisons of scores, the Kruskal–Wallis test followed by Dunn's
multiple comparison test was used. Differences in frequencies were
statistically analyzed by Fisher's exact test. A Pb0.05 was con-
sidered significant.
Results
Selection of PB-responders and nonresponders
With the dosing protocol used for selection of responders and
nonresponders, PB induced marked sedation and ataxia, indicating
that maximum tolerated doses were used. Analysis of plasma drug
concentrations showed that drug concentrations within or above
the therapeutic range (10–40 μg/ml) known from patients with
epilepsy were maintained in all rats throughout the period of
treatment.BAA receptor in coronal sections of the hippocampal formation of a sham
resistant (NIH 18; G–I) epileptic rat. B, E and H show high magnifica-
icrographs of the CA1 sector of the same rats. Scale bars: in A=500 μm (for
from the right (ipsilateral) hemisphere.
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rats showed complete control of seizures and two other rats exhibited
a N75% reduction of seizure frequency. These 8 rats were considered
responders. In 6 other rats, PB did not exert an anticonvulsant effect,
so that these rats were considered nonresponders. One rat (NIH 10;
not included in the responder/nonresponder subgroups) did exhibit
only one seizure each during the two-week predrug control and
treatment periods and was therefore not assigned to any of the PB
subgroups. As in our previous studies (Brandt et al., 2004, 2006;
Volk and Löscher, 2005; Volk et al., 2006), the severity or duration of
the initial brain insult (the SE) did not differ between responders and
nonresponders, indicating that the different AED response in the two
subgroups is likely to be genetically determined.
From the 8 responders and 6 nonresponders thus selected, 5
responders and 5 nonresponders were randomly chosen for immu-
nohistochemistry of GABAA receptor subunits (Fig. 1). Seizure data
from these 5 responders and 5 nonresponders are shown inTable 1 and
Fig. 2. When SRS of all 10 rats were used for comparison between
predrug, drug and postdrug seizure frequencies (Fig. 2A), no sig-
nificant difference between predrug and drug periods was determined.
In contrast, the drug period of the responder subgroup differed
significantly from both pre- and postdrug control periods in that none
of the 5 responders exhibited any seizures during treatment with PB
(Fig. 2B). Nonresponders did not show any significant difference in
seizure frequency over the three recording periods (Fig. 2C). Plasma
levels of PB did not differ significantly between groups and were
within the therapeutic range (10–40 μg/ml) in both responders and
nonresponders (Fig. 2D). As reported previously (Brandt et al., 2004,Fig. 7. Comparison of immunohistochemical labeling for the α3-subunit of the GA
control (A–C), a phenobarbital-responsive (NIH 25; D–F) and a phenobarbital-r
photomicrographs of the dentate hilus and C, F and I high magnification photomicr
D, G), in B=200 μm (for B, E, H), in C=200 μm (for C, F, I). All panels are fro2006; Volk and Löscher, 2005; Volk et al., 2006), on average
nonresponders tended to have more seizures during control periods
than responders, which, however, was not statistically significant
because of large inter-individual variation in seizure frequencies (see
Table 1 and Fig. 2 legend).
Differences in neuropathology between responders and nonresponders
As reported recently for another group of PB-selected epi-
leptic rats (Volk et al., 2006), PB nonresponders differed striking-
ly from responders in hippocampal damage. Visual inspection of
thionin-stained sections did not indicate any difference between
PB-responding epileptic rats and non-epileptic controls (sham or
naive) (Fig. 3). The only exception was one rat (NIH 7) of the 8
PB-responders that showed obvious bilateral damage (score 2–3)
in CA1, CA3 and hilus (not illustrated). In contrast, except one
rat (NIH 13), all nonresponders exhibited neuronal damage in the
hippocampal formation, with neuron loss in CA1, CA3 and/or
dentate hilus (Fig. 3). In the nonresponder NIH13, no obvious
damage was seen in CA1 or CA3, but a clear reduction of
number of neurons in the hilus was visible (Table 1). When the
number of rats with obvious damage in CA1, CA3 and hilus was
statistically compared between the responder and nonresponder
subgroups, the difference in incidence of neurodegeneration in
PB-responders (1/8) and PB nonresponders (5/6) was significant
(P=0.0256).
The presence of histological injury per subregion in the rats
randomly chosen forGABAA receptor immunohistochemistry is shownBAA receptor in coronal sections of the hippocampal formation of a sham
esistant (NIH 17; G–I) epileptic rat. B, E and H show high magnification
ographs of the CA1 sector of the same rats. Scale bars: in A=500 μm (for A,
m the right (ipsilateral) hemisphere.
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counting neurons in the hilus and scoring damage in CA1 and CA3c/
CA4 are shown in Fig. 4. PB-nonresponders exhibited a significant
reduction in number and density of hilar neurons, whereas no such
reduction was seen in responders (Figs. 4A, B). The area of the hilus
was not significantly different between groups (not illustrated). Visual
scoring of damage in CA1 and CA3c/CA4 revealed significant damage
in the nonresponders but not the responder subgroup (Figs. 4C, D). For
the responder group, it is important to note that the only responder with
obvious damage (NIH7)was not included in the 5 responders randomly
chosen for GABAA receptor immunohistochemistry (Table 1).
The CA2 and granule cell layer of the dentate gyrus were
spared from damage in most nonresponders (not illustrated). How-
ever, granule cell dispersion was observed in two of the five non-
responders (not illustrated). Furthermore, hippocampal atrophy or
deformation was seen in most nonresponders. Overall, there was
no obvious correlation between seizure frequencies and hippo-
campal damage, because nonresponders with low seizure fre-
quency did not differ in severity of damage from nonresponders
with high seizure frequency, substantiating previous experiments in
another group of nonresponders (Volk et al., 2006).
Differences in the expression of GABAA receptor subunits between
responders and nonresponders
In non-epileptic controls, the distribution of the GABAA receptor
subunits α1, α2, α3, α4, α5, β2/3, and γ2 in the hippocampalFig. 8. Comparison of immunohistochemical labeling for the α4-subunit of the GA
control (A–C), a phenobarbital-responsive (NIH 21; D–F) and a phenobarbital-r
photomicrographs of the dentate hilus and C, F and I high magnification photomicr
CA1 pyramidal cell layer of the nonresponder (arrow). Scale bars: in A=500 μm (fo
are from the right (ipsilateral) hemisphere.formation was similar to that described previously (Fritschy and
Möhler, 1995; Schwarzer et al., 1997; Sperk et al., 1997). No
differences were seen between naive controls and sham controls.
The α1-subunit was found throughout the dendritic areas of the
hippocampus proper, in the strata oriens and radiatum of CA1 to
CA3, the stratum lacunosum moleculare, and in the molecular
layer of the dentate gyrus (Figs. 5A–F). A considerable amount of
the α1-immunoreactivity was located in perikarya and fibres of
interneurons including basket cells in the dentate gyrus (Figs. 5B,
E). In most epileptic rats, a reduction of α1-immunoreactivity was
observed, which, however, was much more pronounced in PB-
nonresponders (Figs. 5J–L) compared to responders (Figs. 5G–I).
Although not quantified, the number of stained interneurons ap-
peared to be reduced in nonresponders (Fig. 5K).
The α2-subunit was found in fibres of all hippocampal subfields
(Figs. 6A–C). It was especially enriched in the molecular layer of
the dentate gyrus and was more concentrated in CA3 than in CA1.
Staining intensity was reduced in epileptic rats, particularly in PB-
nonresponders (Figs. 6D–I).
α3-Immunoreactivity was generally weak (Fig. 7). Faint staining
was observed in pyramidal cell layers (CA1, CA3), the granule cell
layer of the dentate gyrus and the stratum moleculare. (Figs. 7A–C).
In the hilus, perikarya and fibres were visible (Fig. 7B). Staining in
epileptic rats appeared comparable to that seen in controls.
α4-Immunoreactivity was concentrated in the molecular layer
of the dentate gyrus (Figs. 8A–C). Faint staining was observed
in the strata oriens and radiatum of CA1. In other parts of theBAA receptor in coronal sections of the hippocampal formation of a sham
esistant (NIH 13; G–I) epileptic rat. B, E and H show high magnification
ographs of the CA1 sector of the same rats. Note the increased staining in the
r A, D, G), in B=200 μm (for B, E, H), in C=200 μm (for C, F, I). All panels
178 K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187hippocampus marginal staining was detected. No obvious dif-
ferences were observed between epileptic rats and controls except
for the CA1 sector, in which some PB-nonresponders showed an
upregulation of α4-immunoreactivity in the stratum pyramidale
(Fig. 8I).
The α5-subunit was present at high concentrations in the strata
radiatum and oriens of CA1 and CA2, whereas almost no staining
was present in the hilus, granule cell layer and stratummoleculare of
the dentate gyrus (Figs. 9A–C). In PB-nonresponders, staining was
markedly reduced compared to controls (Figs. 9G–I). The most
marked decrease was determined in CA2, in which α5-staining was
completely lost in several of the nonresponders (Figs. 9G, I).
The β2/3-subunit was present throughout the dendritic areas of
the hippocampus, the strata oriens and radiatum of CA1 to CA3 and
the molecular layer of the dentate gyrus (Figs. 10A–C). No im-
munoreactivity of principal neurons was observed within the
pyramidal cell layers, but interneurons were labelled in the hilus
and other parts of the hippocampal formation. In epileptic rats, a
general reduction of β2/3-immunoreactivity was observed, which
was much more pronounced in PB-nonresponders (Figs. 10G–I)
compared to responders (Figs. 10D–F). Although not quantified, the
number of stained interneurons appeared to be reduced.
γ2-Immunoreactivity was concentrated in dendrites of the stra-
tum radiatum of CA1 to CA3, in the stratum lacunosum moleculare
and in the molecular layer of the dentate gyrus (Figs. 11A–C).
Prominent γ2-immunoreactivity was also present in perikarya located
throughout the dentate hilus. In epileptic rats, a general reduction ofFig. 9. Comparison of immunohistochemical labeling for the α5-subunit of the GA
control (A–C), a phenobarbital-responsive (NIH 23; D–F) and a phenobarbital-r
photomicrographs of the dentate hilus and C, F and I high magnification photomicr
staining in the CA2 sector of the nonresponder (arrow). Scale bars: in A=500 μm (fo
are from the right (ipsilateral) hemisphere.γ2-immunoreactivity was observed, which was much more pro-
nounced in PB-nonresponders (Figs. 11G–I) compared to responders
(Figs. 11G–I).
Since the main aim of this study was to evaluate whether the
expression of GABAA receptor subunits in the hippocampal
formation is different between pharmacoresistant and pharmacor-
esponsive epileptic rats, semi-quantitative image analysis of relative
optical density was used for group comparisons. The alterations in
immunoreactivity for GABAA receptor subunits in the hippocampal
formation of epileptic rats are shown in Figs. 12–15. Naive controls
and sham controls did not significantly differ in the expression of
any subunit. In PB-responders, several alterations were observed
compared to controls, including decreases in α2-staining in the CA3
and hilus, α3-staining in the CA1 and hilus, α4-staining in the CA3,
α5-staining in the CA1, CA3 and hilus, β2/3-staining in CA1, CA3,
dentate gyrus and hilus, and γ2-staining in the CA1, CA3 and hilus.
Because Houser and Esclapez (2003) previously reported that in
epileptic rats the α5-subunit is particularly downregulated in CA2,
we examined α5-immunoreactivity also in this sector, in which
neurons were generally preserved in both responders and non-
responders. In PB-responders, α5-staining was decreased in the
contralateral CA2 sector (Fig. 15A). There was a trend for redu-
ced α1-staining in hippocampal subregions of responders, which,
however, did not reach statistical significance (Figs. 12 and 13).
Furthermore, except for the β2/3-subunit (Fig. 14), no alterations in
any subunit were observed in the granule cell layer and stratum
moleculare of the dentate gyrus of PB-responders (Fig. 13).BAA receptor in coronal sections of the hippocampal formation of a sham
esistant (NIH 18; G–I) epileptic rat. B, E and H show high magnification
ographs of the CA2 sector of the same rats. Note the almost complete loss of
r A, D, G), in B=200 μm (for B, E, H), in C=100 μm (for C, F, I). All panels
Fig. 10. Comparison of immunohistochemical labeling for the β2/3-subunit of the GABAA receptor in coronal sections of the hippocampal formation of a control
(A–C), a phenobarbital-responsive (NIH 31; D–F) and a phenobarbital-resistant (NIH 8; G–I) epileptic rat. B, E and H show high magnification
photomicrographs of the dentate hilus and C, F and I high magnification photomicrographs of the CA3 sector of the same rats. Note the almost complete loss of
staining in CA3 of the nonresponder. Scale bars: in A=500 μm (for A, D, G), in B=200 μm (for B, E, H), in C=200 μm (for C, F, I). All panels are from the right
(ipsilateral) hemisphere.
179K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187In contrast to responders, much more marked and widespread
reductions in immunoreactivity of GABAA receptor subunits were
determined in PB-nonresponders (Figs. 12–15). In CA1 and CA3,
these alterations were not solely due to cell loss, but were also
observed in rat NIH13, i.e., the nonresponder that did not exhibit any
obvious neurodegeneration in these areas (see above). Significant
differences between responders and nonresponders were determined
forα1-, α4- and α5-staining in theCA1. Furthermore, alterations in the
β2/3-subunit differed between responders and nonresponders in that
significant decreases in the ipsilateral CA1, dentate gyrus and hilus
were only seen in nonresponders (Fig. 14). Because the granule cell
layer of the dentate gyrus and the CA2 were precluded from cell loss
in most nonresponders, alterations in expression of GABAA receptor
subunits in these regions were of particular interest. As shown in Figs.
13 and 14, significant reductions of α1, α2, α5, β2/3 and γ2-
immunoreactivity were determined in PB-nonresponders in the
dentate gyrus. Furthermore, a significant reduction in α5-staining
was determined in the CA2 of both hemispheres (Fig. 15A). The
upregulation of α4-immunoreactivity in the CA1 pyramidal cell layer
(Fig. 8 I) was not determined by semi-quantitative image analysis of
relative optical density of the CA1 (Fig. 12), most likely because
stratum oriens and stratum radiatumwere included in theOD analysis.
Therefore, we repeated the densitometric measurement but, instead of
using field densitometry, analyzed the expression of the α4-subunit
only in pyramidal cells of the CA1 layer (Fig. 15B). By this
measurement, a significant upregulation of the α4-subunit was
determined in CA1 pyramidal cells of nonresponders (Fig. 15B), thussubstantiating the impression obtained by visual assessment of
sections (Fig. 8I).
Discussion
PB-resistant rats differ from responsive rats in GABAA receptor
subunit expression in the hippocampal formation
This is the first study demonstrating that AED-resistant rats differ
from drug responsive rats in GABAA receptor subunit expression in
a model of TLE. Overall, seven GABAA receptor subunits were
analyzed in four hippocampal subregions in both hemispheres (plus
α5-staining in the CA2), resulting in a total number of 58 sets of data
in four groups of rats (Figs. 12–15). PB-nonresponders significantly
differed from controls in 44 of these 58 sets of data, compared to 20/
58 in responders (Pb0.0001), underlining the remarkable difference
between PB-responders and nonresponders in hippocampal expres-
sion of GABAA receptor subunits. The most striking difference was
observed in the expression of the α1-subunit, which was reduced in
all examined regions of nonresponders, but was not different from
controls in responders. Widespread reductions were also determined
for the α2-, β2/3 and γ2-subunits in nonresponders. In the dentate
gyrus (granule cell layer, stratum moleculare), except for the β2/3-
subunit, significant differences to controls were only determined in
nonresponders. In general, all alterations in GABAA receptor
subunit expression indicated by the field densitometric OD analyses
in nonresponders were reductions in immunoreactivity, but none of
Fig. 11. Comparison of immunohistochemical labeling for the γ2-subunit of the GABAA receptor in coronal sections of the hippocampal formation of a sham
control (A–C), a phenobarbital-responsive (NIH 31; D–F) and a phenobarbital-resistant (NIH 6; G–I) epileptic rat. B, E and H show high magnification
photomicrographs of the dentate hilus and C, F and I high magnification photomicrographs of the CA3 sector of the same rats. Scale bars: in A=500 μm (for A,
D, G), in B=200 μm (for B, E, H), in C=100 μm (for C, F, I). All panels are from the right (ipsilateral) hemisphere.
180 K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187the subunit immunoreactivities increased compared to controls.
During visual inspection of sections, however, an increase in α4-
immunoreactivity was observed in the CA1 pyramidal cell layer of
PB-nonresponders, which was confirmed by densitometry of CA1
pyramidal cells.
GABAA receptors are heteropentameric membrane proteins that
form aGABA-gated Cl− channel (Rudolph andMöhler, 2006). Based
on the presence of 8 subunit families comprising at least 18 subunits,
GABAA receptors display an extraordinary structural heterogeneity
(Möhler et al., 2002). Receptors containing the α1-, α2-, α3-, or α5-
subunit, a β-subunit (mainly β2 or β3) and, in nearly all cases, the γ2-
subunit in a 2:2:1 stoichiometry aremost prevalent in the brain and are
characterized by their sensitivity to benzodiazepines (Möhler et al.,
2002). Receptors containing the α4-subunit are generally expressed at
very low abundance but more prominently in thalamus and dentate
gyrus (Möhler et al., 2002). The α4-subunit is coassembled with
the γ- or δ-subunit in benzodiazepine insensitive receptors (Möhler
et al., 2002). In addition to benzodiazepines, GABAA receptors
represent the sites of action of barbiturates, neurosteroids and, at
least in part, some general anesthetics (Möhler et al., 2002; Olsen,
2002; Rogawski and Löscher, 2004; Rudolph and Möhler, 2006).
PB-resistant rats differ from responsive rats in neurodegeneration
of the hippocampal formation
Most previous studies on GABAA receptor subunit alterations after
SEhave used the pilocarpine or kainatemodels ofTLE. In thesemodels,
widespread brain damage is induced in most rats, which differentiatethese models from the model used in the present study, in which brain
damage is much less severe (Brandt et al., 2003). Furthermore, not all
rats developing epilepsy after electrically induced SE exhibit
neurodegeneration in the hippocampus, indicating that such neurode-
generation is not necessary for development of epilepsy with SRS after
SE (Volk et al., 2006). Thus, by comparing epileptic rats with and
without hippocampal damage, this model provides an opportunity to
study the functional consequences of the damage. Using stereological
counting of neurons in different subfields of the hippocampal formation,
we have shown recently that loss of neurons in CA1, CA3 and dentate
hilus only occurs in PB-nonresponders, whereas responders do not
differ in neuronal counts from controls, indicating that neurodegenera-
tion is involved in the mechanisms underlying resistance to treatment
(Volk et al., 2006). In the present study, this recent observation was
confirmed in another group of epileptic rats in that hippocampal damage
was associated with resistance to PB, whereas most PB-responders did
not show any obvious damage. By combining the data of the two
studies, one of 15 responders exhibited hippocampal damage compared
to 9 of 10 nonresponders (Pb0.0001). Clinically, it is well established
that hippocampal sclerosis is often associated with resistance to AEDs
(Schmidt and Löscher, 2005), so that our experimental observations in a
rat model of TLE are in line with clinical experience.
Alterations in GABAA receptor subunit expression in other rat models
of TLE
The widespread damage to the hippocampus and afferent
regions, such as the piriform cortex, developing after pilocarpine
Fig. 12. Quantitative analysis of the relative optical density of GABAA receptor subunit immunoreactivities in the CA1 and CA3 regions of naive controls, sham
controls, and epileptic rats either responding or not responding to treatment with phenobarbital. CA1 and CA3 measurements by field densitometry included stratum
pyramidale, stratum oriens and stratum radiatum and are shown separately for the hemisphere ipsilateral and contralateral to the stimulation electrode in the basolateral
amygdala. Data aremeans±SEMof five rats per group.When analysis of data byANOVA indicated significant differences (Pb0.05) between groups, posthoc testing
was used to localize the group differences. Such significant differences between groups are indicated by asterisks (⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001).
181K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187
Fig. 13. Quantitative analysis of the relative optical density of GABAA receptor subunit immunoreactivities in the dentate gyrus (DG) and dentate hilus of naive
controls, sham controls, and epileptic rats either responding or not responding to treatment with phenobarbital. Dentate gyrus measurements by field
densitometry included granule cell and molecular layers and dentate hilus measurements included polymorphic hilus neurons, but excluded neurons from the
CA3c (also termed CA4) sector reaching into the hilus. All measurements are shown separately for the hemisphere ipsilateral and contralateral to the stimulation
electrode in the basolateral amygdala. Data are means±SEM of five rats per group. When analysis of data by ANOVA indicated significant differences (Pb0.05)
between groups, posthoc testing was used to localize the group differences. Such significant differences between groups are indicated by asterisks (⁎Pb0.05;
⁎⁎Pb0.01).
182 K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187and kainate induced SE in rats is associated with acute and chronic
changes in GABAA receptor expression in the hippocampal
formation (Rice et al., 1996; Schwarzer et al., 1997; Tsunashima
et al., 1997; Brooks-Kayal et al., 1998; Sperk et al., 1998; Fritschy
et al., 1999; Houser and Esclapez, 2003). These alterations arecomplex and include both upregulation and downregulation of
different subunits as well as regional differences in the subunit
expression between the hippocampus and the dentate gyrus.
Furthermore, due to compensatory changes, alterations in subunit
expression observed at early intervals (hours/days/a fewweeks) after
Fig. 14. Quantitative analysis of the relative optical density of the β2/3 GABAA receptor subunit immunoreactivities in the hippocampal formation of naive
controls, sham controls, and epileptic rats either responding or not responding to treatment with phenobarbital. CA1 and CA3measurements by field densitometry
included stratum pyramidale, stratum oriens and stratum radiatum, dentate gyrus measurements included granule cell and molecular layers, and dentate hilus
measurements included polymorphic hilus neurons, but excluded neurons from the CA3c (also termed CA4) sector reaching into the hilus. All measurements are
shown separately for the hemisphere ipsilateral and contralateral to the stimulation electrode in the basolateral amygdala. Data are means±SEM of five rats per
group. When analysis of data by ANOVA indicated significant differences (Pb0.05) between groups, posthoc testing was used to localize the group differences.
Such significant differences between groups are indicated by asterisks (⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001).
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weeks). In the CA1 and CA3 pyramidal cell layers and the dentate
hilus of pilocarpine or kainate-treated rats, marked reductions
related to neuronal cell death were seen in most subunits (Rice et al.,
1996; Schwarzer et al., 1997; Fritschy et al., 1999; Houser and
Esclapez, 2003). In the CA3 sector of kainate-treated rats,
considerable recovery in immunoreactivity of several subunits
(notably of α2, α5, β3 and γ2) occurred at late intervals (Schwarzer
et al., 1997), which, however, was not observed in the pilocarpine
model (Fritschy et al., 1999). In the stratum pyramidale of CA2,
which is generally preserved in rat models of TLE, a large decrease
in labeling of the α5-subunit, but not the α2-subunit, was observed at
three–four months after pilocarpine-induced SE (Houser and
Esclapez, 2003). In the dentate gyrus, decreased expression of a
few GABAA receptor subunits, most notably the α1 subunit, has
been found in some reports (Tsunashima et al., 1997; Brooks-Kayal
et al., 1998), but the predominant change of GABAA receptor
subunits in the granule cell and molecular layers of the dentate gyrus
is upregulation ofmost subunits, reflecting compensatory changes in
response to increased excitability within this area (Schwarzer et al.,
1997; Sperk et al., 1998; Fritschy et al., 1999).
Only a few studies have examined acute and chronic alterations
in GABAA receptor subunits following electrical induction of SE
(Laurén et al., 2003; Nishimura et al., 2005). When the expression
of α2, α4, β3, and γ2 subunit mRNAs was determined three months
after SE induced by electrical stimulation of the lateral amygdaloidnucleus, α2 expression was decreased in CA3, and α4 in CA1, but
β3 was increased in all subregions, in particular in the granule cell
layer (Laurén et al., 2003). Nishimura et al. (2005) investigated
changes in the mRNA expression of nine major GABAA receptor
subunits 24 h and 30 days following SE induced by electrical
stimulation of the hippocampus. In cornu ammonis, persistent
decreases in α2, α5 and β2 subunits were determined in CA1,
whereas only the α5 subunit was persistently decreased in the CA3.
Expression of the β3-subunit was increased after 30 days in CA3.
In the dentate granule cells, α5 and δ-subunit mRNA expression
decreased, accompanied by persistent increases in α4, β2, and β3
subunits (Nishimura et al., 2005). To our knowledge, immuno-
reactivity of GABAA receptor subunits has not been previously
studied in rats developing epilepsy after electrically induced SE.
Alterations in GABAA receptor subunit expression in the present
rat model of TLE and comparison with respective changes in
human TLE
In the present study, rats were killed several months after SE, so
that the observed changes in GABAA receptor subunit expression
reflect long-term abnormalities. In PB-responders, several altera-
tions in subunit expression were observed, including decreases in
α2-immunoreactivity in the CA3 and hilus, α3-immunoreactivity
in the CA1 and hilus, α4-immunoreactivity in the CA3, α5-staining
in the CA1, CA2, CA3 and hilus, β2/3-immunoreactivity in
Fig. 15. (A) Quantitative analysis of the relative optical density of the α5-subunit of the GABAA receptor in the CA2 sector of naive controls, sham controls, and
epileptic rats either responding or not responding to treatment with phenobarbital. CA2 measurements by field densitometry included stratum pyramidale,
stratum oriens and stratum radiatum and are shown separately for the hemisphere ipsilateral and contralateral to the stimulation electrode in the basolateral
amygdala. Data are means±SEM of five rats per group. Analysis of data by ANOVA indicated significant differences (Pb0.05) between groups for
both hemispheres. Significant differences between groups obtained by posthoc testing are indicated by asterisks (⁎Pb0.05; ⁎⁎Pb0.01; ⁎⁎⁎Pb0.001).
(B) Quantitative analysis of the relative optical density of the α4-subunit of the GABAA receptor in CA1 pyramidal cells of naive controls, sham controls, and
epileptic rats either responding or not responding to treatment with phenobarbital. Data are means±SEM of five rats per group and are shown as percent control.
Analysis of data by ANOVA indicated significant differences (Pb0.05) between groups for both hemispheres. Significant differences between groups obtained
by posthoc testing are indicated by asterisk (⁎Pb0.05).
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in the CA1, CA3 and hilus. Except for β2/3, no alterations in
subunit expression were determined in the dentate gyrus, and the
α1-subunit was not altered in any region. Furthermore, no
upregulation of any subunit was observed in PB-responders. Since
alterations in GABAA receptor subunits of PB-responders occurred
in the absence of any obvious neurodegeneration, these findings
support the idea that decreased expression of such subunits in
epileptic tissue is not merely an indication of neuronal loss but
represents downregulated expression of subunits in undamaged
structures. Much more widespread reductions in immunoreactivity
of GABAA receptor subunits were determined in PB-nonrespon-
ders, including a pronounced decrease of α1-subunit expression in
the dentate gyrus. Furthermore, an increase in α4-immunoreactivity
was observed in the CA1 pyramidal cell layer of nonresponders.
The differences in subunit alterations between responders and
nonresponders are presumably, at least in part, a consequence of
neurodegeneration in the hippocampal formation, which was
determined in nonresponders but not responders. However, there
was no simple correlation between loss of neurons and reduction of
GABAA receptor subunit expression in PB-nonresponders because
such reduction was also seen in a nonresponder (NIH13) that did notexhibit any obvious neurodegeneration in most hippocampal
subfields. However, with respect to the apparent lack of neuronal
loss in this nonresponder and most responders, it has to be considered
that visible comparison of stained sections is not always sensitive
enough to assess for small degrees of neuronal loss, which could
influence the evaluation of GABAA receptor subunit expression.
When the alteration in GABAA receptor subunits in PB-resistant
rats of the present model of TLE are compared with respective
alterations found in hippocampi of patients undergoing surgery for
medically intractable epilepsy (Loup et al., 2000), both PB-resistant
rats and patients with hippocampal sclerosis exhibited decreased
GABAA receptor subunit staining, reflecting cell loss, in CA1, CA3,
and hilus. In the dentate gyrus of refractory TLE patients, however,
increased staining of the α2-subunit and, in part, the α1 and γ2
subunits was observed in the granule cell and molecular layers,
which was not observed in PB-resistant rats. Upregulation of
GABAA receptors in the dentate gyrus has been proposed to result
from hyperactivity of GABA synapses in the dentate granule cells
(Schwartzkroin, 1998). The apparent lack of such upregulation in
the present study may thus indicate that GABA synapses in the
dentate granule cells are not hyperactive in the rat model used for our
experiments.
185K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187We plan to perform neurophysiologic studies in PB-responders
and nonresponders to examine this possibility in detail.
Pharmacological consequences of alterations in GABAA receptor
subunit expression
It is tempting to speculate that the extensive alterations in the
expression of GABAA receptor subunits observed in nonresponders
are associated with alterations in the pharmacology of AEDs that act
via GABAA receptors. We have previously reported that the
morphological alterations in PB-nonresponders were associated
with striking alterations in autoradiographic imaging of diazepam-
sensitive and diazepam-insensitive GABAA receptor binding in the
dentate gyrus with a significant shift to enhanced diazepam-
insensitive binding (Volk et al., 2006). Furthermore, diazepam-
sensitive binding was decreased in the hilus of PB-nonresponders,
whereas PB-responders did not differ significantly in diazepam-
sensitive or insensitive binding from controls in any region. Based
on these data, we suggested that the remarkable increase of
diazepam-insensitive binding in nonresponders indicates that the
expression of a selective population of GABAA receptors is strongly
upregulated in the dentate granule cells when extensive cell loss
occurs in the hilus (Volk et al., 2006). These receptors likely contain
the α4 and δ subunits (Whiting et al., 2000), which correspond to a
major population of GABAA receptors mediating tonic inhibition in
the dentate gyrus (Peng et al., 2004; Stell andMody, 2002;Wei et al.,
2003). An increase in diazepam-insensitive GABAA receptors has
previously been reported for epileptic rats of the pilocarpine model
of TLE (Brooks-Kayal et al., 1998; Coulter, 2000). However, in the
present study no upregulation of the α4-subunit was observed in the
dentate gyrus of PB-nonresponders. Unfortunately, because of
technical reasons (see Materials and methods), we could not analyze
the δ subunit in the present study, so that we cannot exclude the
possibility that the increases in diazepam-insensitive GABAA
receptor binding recently observed in PB-nonresponders were
related to changes in the δ-subunit.
PB's anticonvulsant effect is thought to be primarily related to
enhancement of GABA-mediated inhibitory synaptic transmission
via modulation of GABAA receptors (Olsen, 2002; Rogawski and
Löscher, 2004). Although the effects of barbiturates on the GABAA
receptor depend largely on the β-subunit, their agonist activity is
substantially influenced by the α-subunit subtype (Bureau and
Olsen, 1993; Mathews et al., 1996; Thompson et al., 1996; Drafts
and Fisher, 2006; Zeller et al., 2007). Direct comparisons between
the effects of the more potent anesthetic barbiturate pentobarbital
and PB on GABAA receptors have shown both quantitative and
qualitative differences between these drugs, indicating that PB may
act as a partial or subtype-selective agonist (Wong et al., 1984;
Dunwiddie et al., 1986;Olsen, 2002). Themarked decreases in β- and
α-subunits observed in nonresponders are likely to reduce the effect
of PB on GABAA receptors and thus could be involved in the lack of
anticonvulsant efficacy of PB in these animals. The consequences of
target loss for PB are increased by overexpression of the drug efflux
transporter P-gp in the blood-brain barrier of PB-nonresponders
(Volk and Löscher, 2005), which likely reduces the concentration of
PB at its brain targets (Löscher and Potschka, 2005). This hypothesis
is substantiated by our recent finding that the PB-resistance in PB-
nonresponders can be counteracted to a large extent by inhibiting P-
gp (Brandt et al., 2006), which leads to increased brain concentra-
tions of PB (Potschka et al., 2002; Hoffmann and Löscher, 2007).
Thus, based on this hypothesis, both reduction of target sensitivityand decreased PB levels at its targets contribute to PB-resistance.We
are currently determining whether resistance to PB extends to other
AEDs that act via GABAA receptors, including drugs that are not
substrates for P-gp. As described recently (Volk et al., 2006), we
believe that overexpression of P-gp, neurodegeneration and
alterations in AED targets act in concert to mediate AED resistance.
The observations of the present experiments strongly indicate that
AEDs that act via GABAA receptors will be affected by the
extensive alterations in the expression of GABAA receptor subunits
in PB-nonresponders.
Potential involvement of alterations in GABAA receptor subunit
expression in epileptogenesis
We have shown previously that the severity or duration of the
initial brain insult (the SE) did not differ between PB-responders or
nonresponders, indicating that the differences between the two
subgroups are likely to be genetically determined (Volk et al.,
2006). Although several nonresponders exhibit more spontaneous
seizures than responders, other nonresponders do not, so that there
is no significant difference in average seizure frequency between
the nonresponder and responder groups (Brandt et al., 2004; 2006;
Volk et al., 2006; and present study). This would seem to indicate
that morphological or neurochemical changes that are only present
in PB-nonresponders are not critical for development of epilepsy in
these animals. As discussed above, the lack of any obvious
hippocampal damage in most PB-responders indicate that such
neurodegeneration is not necessary for development of epilepsy
with SRS after SE. Furthermore, the lack of persistent alterations in
GABAA receptor subunit expression in the dentate gyrus of PB-
responders may indicate that such alterations, which were observed
in PB-nonresponders, are not critically involved in the chronic
epileptic state. However, since only one late time point after SE
was used for analyses of GABAA receptor subunits, we cannot
exclude that comparable alterations in subunits were present at
earlier time points in both responders and nonresponders and that
such alterations were involved in epileptogenesis. Despite various
studies demonstrating complex alterations in GABAA receptor
subunits in rats and humans with epilepsy, it remains an open ques-
tion whether such changes are critical events in the epileptogenic
process, or whether they are only an epiphenomenon related to loss of
neurons or compensatory and triggered by the repeated occurrence of
spontaneous seizures (Schwartzkroin, 1998). The first direct evidence
that alterations in GABAA receptor subunits developing after SE are
involved in epileptogenesiswas recently reported byRaol et al. (2006)
who showed that counteracting the reduced expression of α1-subunit
expression in the dentate gyrus by gene transfer inhibits the de-
velopment of spontaneous seizures in the pilocarpine model.
Conclusions
As shown by our studies, epileptic rats that are resistant to treatment
with PB exhibit complex morphological and neurochemical brain
alterations compared to PB-responsive rats, including hippocampal
damage, overexpression of P-gp in the hippocampus and piriform
cortex, enhanced diazepam-insensitive GABAA receptor binding in the
dentate gyrus, and widespread alterations in GABAA receptor subunits
in the hippocampal formation (Volk and Löscher, 2005; Volk et al.,
2006; present study). We have recently shown that the resistance to PB
in our model extends to other AEDs (Bethmann et al., 2007), indicating
that PB-nonresponders have amultidrug resistant type of TLE similar to
186 K. Bethmann et al. / Neurobiology of Disease 31 (2008) 169–187patients with TLE who are resistant to multiple AEDs with different
mechanisms of action (Schmidt and Löscher, 2005). The variety of
changes in AED-resistant rats makes it particularly challenging to
determine the functional significance of each of these alterations.
Nevertheless, consideration of the individual changes could provide
clues to the cellular basis of drug resistant epilepsy and may lead to
novel therapeutic strategies.
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